You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrimetrexate
Accession NumberDB01157  (APRD00268)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. [PubChem]
Structure
Thumb
Synonyms
CI-898
Neutrexin
TMQ
TMX
Trimetrexate
Trimetrexato
Trimetrexatum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Neutrexin Pws IV 25mg/vialPowder, for solution25 mgIntravenousMedimmune Oncology, Inc.1994-12-312007-02-21Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
NeutrexinNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIUPN4ITI8T4
CAS number52128-35-5
WeightAverage: 369.4176
Monoisotopic: 369.180089627
Chemical FormulaC19H23N5O3
InChI KeyNOYPYLRCIDNJJB-UHFFFAOYSA-N
InChI
InChI=1S/C19H23N5O3/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24)
IUPAC Name
5-methyl-6-{[(3,4,5-trimethoxyphenyl)amino]methyl}quinazoline-2,4-diamine
SMILES
COC1=CC(NCC2=C(C)C3=C(C=C2)N=C(N)N=C3N)=CC(OC)=C1OC
Pharmacology
IndicationFor use, with concurrent leucovorin administration (leucovorin protection), as an alternative therapy for the treatment of moderate-to-severe Pneumocystis carinii pneumonia (PCP) in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS). Also used to treat several types of cancer including colon cancer.
Structured Indications Not Available
PharmacodynamicsTrimetrexate, a non-classical folate antagonist, is a synthetic inhibitor of the enzyme dihydrofolate reductase (DHFR). During DNA synthesis and cellular reproduction, folic acid is reduced to tetrahydrofolic acid by the enzyme folic acid reductase. By interfering with the reduction of folic acid, trimetrexate interferes with tissue cell reproduction. Generally, the most sensitive cells to the antimetabolite effect of trimetrexate are those cells which are most actively proliferating such as malignant cells, dermal epithelium, buccal and intestinal mucosa, bone marrow, fetal cells, and cells of the urinary bladder. Because the proliferation of cells in malignant tissues is greater than in most normal tissues, trimetrexate may impair the growth of the malignant tissues without causing irreversible damage to normal tissues. Due to very serious and potentially life-threatening side-effects of this drug, leucovorin must be co-administered for at least 72 hours after the last dose.
Mechanism of actionIn vitro studies have shown that trimetrexate is a competitive inhibitor of dihydrofolate reductase (DHFR) from bacterial, protozoan, and mammalian sources. DHFR catalyzes the reduction of intracellular dihydrofolate to the active coenzyme tetrahydrofolate. Inhibition of DHFR results in the depletion of this coenzyme, leading directly to interference with thymidylate biosynthesis, as well as inhibition of folate-dependent formyltransferases, and indirectly to inhibition of p.r.n. biosynthesis. The end result is disruption of DNA, RNA, and protein synthesis, with consequent cell death.
TargetKindPharmacological actionActionsOrganismUniProt ID
Dihydrofolate reductaseProteinyes
inhibitor
HumanP00374 details
Related Articles
AbsorptionNot Available
Volume of distribution
  • 20 ± 8 L/m2
  • 36.9 ± 6 L/m2 [cancer patients]
Protein binding95% (over the concentration range of 18.75 to 1000 ng/mL)
Metabolism

Hepatic. Preclinical data strongly suggest that the major metabolic pathway is oxidative O-demethylation, followed by conjugation to either glucuronide or the sulfate.

Route of eliminationTen to 30% of the administered dose is excreted unchanged in the urine.
Half life11 to 20 hours
Clearance
  • 38 +/- 15 mL/min/m2 [patients with acquired immunodeficiency syndrome (AIDS) who had Pneumocystis carinii pneumonia (4 patients) or toxoplasmosis (2 patients). Trimetrexate was administered intravenously as a bolus injection at a dose of 30 mg/m2/day along with leucovorin 20 mg/m2 every 6 hours for 21 days]
  • 53 +/- 41 mL/min/m2 [Cancer patients with advanced solid tumors using various dosage regimensreceiving a single-dose administration of 10 to 130 mg/m2]
  • 30 +/- 8 mL/min/m2 [Cancer patients with advanced solid tumors using various dosage regimensafter a five-day infusion]
ToxicityThe LD50 of intravenous trimetrexate in mice is 62 mg/kg (186 mg/m2). Myelosuppression is a dose-limiting toxic effect.
Affected organisms
  • Humans and other mammals
  • Pneumocystis carinii
  • Bacteria and protozoa
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Trimetrexate.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Trimetrexate.Approved, Investigational
AmrinoneThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Amrinone.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Trimetrexate.Investigational
AzelnidipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Azelnidipine.Approved
AzimilideThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Azimilide.Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Barnidipine.Approved
BenidipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Benidipine.Approved
BepridilThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Bepridil.Approved, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Trimetrexate.Approved, Investigational
BuspironeThe metabolism of Buspirone can be decreased when combined with Trimetrexate.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Trimetrexate.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trimetrexate.Approved
CaiThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Cai.Investigational
CilnidipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Cilnidipine.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Cinnarizine.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Trimetrexate.Approved, Investigational, Withdrawn
ClevidipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Clevidipine.Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Trimetrexate.Approved, Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Trimetrexate.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Trimetrexate.Approved, Investigational, Vet Approved
DarodipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Darodipine.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Trimetrexate.Approved
DidanosineDidanosine can cause a decrease in the absorption of Trimetrexate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Trimetrexate.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Trimetrexate.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Diltiazem.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Trimetrexate.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Trimetrexate.Approved
DotarizineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Dotarizine.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Efonidipine.Approved
EperisoneThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Eperisone.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Trimetrexate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Fendiline.Withdrawn
FlunarizineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Flunarizine.Approved
FosphenytoinThe serum concentration of Trimetrexate can be decreased when it is combined with Fosphenytoin.Approved
GabapentinThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Gallopamil.Investigational
IsradipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Isradipine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Lacidipine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Lamotrigine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Lercanidipine.Approved, Investigational
LosartanThe metabolism of Losartan can be decreased when combined with Trimetrexate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Manidipine.Approved
MibefradilThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Mibefradil.Withdrawn
NaftopidilThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Naftopidil.Investigational
NicardipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nicardipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Niguldipine.Experimental
NiludipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nitrendipine.Approved
OuabainOuabain may decrease the cardiotoxic activities of Trimetrexate.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trimetrexate.Approved, Vet Approved
PerhexilineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Perhexiline.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Trimetrexate.Approved, Vet Approved
PimozideTrimetrexate may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Pinaverium.Approved
PregabalinThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Prenylamine.Withdrawn
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Trimetrexate.Approved, Vet Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Trimetrexate.Approved
RanolazineThe metabolism of Ranolazine can be decreased when combined with Trimetrexate.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Trimetrexate.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Trimetrexate.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Trimetrexate.Approved
RisedronateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Risedronate.Approved, Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Trimetrexate.Approved
SucralfateSucralfate can cause a decrease in the absorption of Trimetrexate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Trimetrexate.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Trimetrexate.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Tolfenamic Acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Trimetrexate.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Verapamil.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Vinpocetine.Investigational
XylometazolineThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Xylometazoline.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Ziconotide.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Trimetrexate.Approved
Food InteractionsNot Available
References
Synthesis Reference

Martin Stogniew, Javad M. Zadei, “Compositions comprising trimetrexate and methods of their synthesis and use.” U.S. Patent US6258821, issued January, 1974.

US6258821
General ReferencesNot Available
External Links
ATC CodesP01AX07
AHFS CodesNot Available
PDB Entries
FDA labelDownload (53.3 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9382
Caco-2 permeable+0.6393
P-glycoprotein substrateSubstrate0.5758
P-glycoprotein inhibitor INon-inhibitor0.5948
P-glycoprotein inhibitor IINon-inhibitor0.6545
Renal organic cation transporterNon-inhibitor0.7837
CYP450 2C9 substrateNon-substrate0.8668
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5206
CYP450 1A2 substrateNon-inhibitor0.5
CYP450 2C9 inhibitorNon-inhibitor0.7037
CYP450 2D6 inhibitorNon-inhibitor0.7397
CYP450 2C19 inhibitorNon-inhibitor0.6512
CYP450 3A4 inhibitorNon-inhibitor0.8614
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6235
Ames testNon AMES toxic0.6339
CarcinogenicityNon-carcinogens0.9136
BiodegradationNot ready biodegradable0.9968
Rat acute toxicity2.3340 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9027
hERG inhibition (predictor II)Non-inhibitor0.6892
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Powder, for solutionIntravenous25 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6017922 No1998-05-182018-05-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point215-217 °CPhysProp
water solubility31.4 mg/LNot Available
logP2.55HANSCH,C ET AL. (1995)
pKa8.0Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0309 mg/mLALOGPS
logP2.36ALOGPS
logP2.28ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)17.04ChemAxon
pKa (Strongest Basic)7.54ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area117.54 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity107.7 m3·mol-1ChemAxon
Polarizability40.24 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassNaphthyridines
Sub ClassQuinazolines
Direct ParentQuinazolinamines
Alternative Parents
Substituents
  • Quinazolinamine
  • Methoxyaniline
  • Methoxybenzene
  • Phenylalkylamine
  • Substituted aniline
  • Phenol ether
  • Benzylamine
  • Anisole
  • Aralkylamine
  • Secondary aliphatic/aromatic amine
  • Aniline
  • Aminopyrimidine
  • Alkyl aryl ether
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • Primary aromatic amine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Azacycle
  • Secondary amine
  • Ether
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Nadph binding
Specific Function:
Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFRL1.
Gene Name:
DHFR
Uniprot ID:
P00374
Molecular Weight:
21452.61 Da
References
  1. Bertino JR, Zhao SC, Mineishi S, Ercikan-Abali EA, Banerjee D: Use of variants of dihydrofolate reductase in gene transfer to produce resistance to methotrexate and trimetrexate. Prog Exp Tumor Res. 1999;36:82-94. [PubMed:10386066 ]
  2. Graffner-Nordberg M, Kolmodin K, Aqvist J, Queener SF, Hallberg A: Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii. J Med Chem. 2001 Jul 19;44(15):2391-402. [PubMed:11448221 ]
  3. Warlick CA, Diers MD, Wagner JE, McIvor RS: In vivo selection of antifolate-resistant transgenic hematopoietic stem cells in a murine bone marrow transplant model. J Pharmacol Exp Ther. 2002 Jan;300(1):50-6. [PubMed:11752096 ]
  4. Zhu WY, Bunni M, Priest DG, DiCapua JL, Dressler JM, Chen Z, Melera PW: Severe folate restriction results in depletion of and alteration in the composition of the intracellular folate pool, moderate sensitization to methotrexate and trimetrexate, upregulation of endogenous DHFR activity, and overexpression of metallothionein II and folate receptor alpha that, upon folate repletion, confer drug resistance to CHL cells. J Exp Ther Oncol. 2002 Sep-Oct;2(5):264-77. [PubMed:12416030 ]
  5. Sweeney CL, Frandsen JL, Verfaillie CM, McIvor RS: Trimetrexate inhibits progression of the murine 32Dp210 model of chronic myeloid leukemia in animals expressing drug-resistant dihydrofolate reductase. Cancer Res. 2003 Mar 15;63(6):1304-10. [PubMed:12649191 ]
  6. Polshakov VI, Birdsall B, Frenkiel TA, Gargaro AR, Feeney J: Structure and dynamics in solution of the complex of Lactobacillus casei dihydrofolate reductase with the new lipophilic antifolate drug trimetrexate. Protein Sci. 1999 Mar;8(3):467-81. [PubMed:10091649 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23